2024-09-02 - Analysis Report
## Lilly (LLY) Stock Analysis

**Company Overview:**  Eli Lilly and Company is a global pharmaceutical company specializing in the development and commercialization of innovative medicines. 

**1. Performance vs. S&P 500:**

* **Cumulative Return:** Lilly (LLY) has a cumulative return of 571.94%, while the S&P 500 (VOO) has a cumulative return of 89.66%.
* **Relative Outperformance:** This means Lilly has significantly outperformed the S&P 500, with a relative outperformance of 482.28, representing a 100% relative outperformance compared to its historical range.

**2. Recent Price Movements:**

* **Closing Price:** $960.02
* **5-day Moving Average:** $950.83
* **20-day Moving Average:** $907.01
* **60-day Moving Average:** $888.73
* **Analysis:** The price is trading above all three moving averages, suggesting positive momentum in the short, medium, and long term. 

**3. Technical Indicators:**

* **RSI:** 78.82 - The RSI is currently in overbought territory, indicating that the stock may be due for a correction. 
* **PPO:** 0.36 -  The PPO indicates positive momentum, but the high RSI suggests that the momentum may be waning. 
* **Delta_Previous_Relative_Divergence:** 18.98 - The positive value suggests that the stock is showing signs of a potential short-term upward trend.
* **Expected Return:** 0.0% - The 5-year expected return is currently at 0%, which is low given the stock's past performance and current trends. This suggests that future returns may be lower than the historical average.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2023-08-08 | 1.96 | $8.31 B |
| 2024-08-08 | 1.96 | $8.31 B |

* **Most Recent Earnings:** The most recent earnings report shows that Lilly exceeded analysts' expectations, posting an EPS of $3.29 compared to an expected EPS of $2.78. Revenue also surpassed expectations, coming in at $11.30 billion. 
* **Analysis:** The strong earnings report shows that Lilly remains a well-performing company, generating robust revenue and earnings growth. 

**5. Overall Analysis:**

Lilly (LLY) has exhibited strong performance, significantly outperforming the S&P 500. Its recent price movements suggest positive momentum, supported by strong earnings and technical indicators. However, the high RSI and low expected return suggest that the stock may be overvalued and that future returns may be lower than historical averages. The high RSI might also indicate a potential short-term correction. 

**6. Recommendations:**

* Investors seeking long-term growth may consider holding or adding to their positions in Lilly (LLY). The company's strong earnings and dominance in the pharmaceutical market suggest a bright future.
* However, given the current high valuation and overbought territory, investors should remain cautious and monitor the stock closely for signs of a correction. 
* Consider dollar-cost averaging or a staggered approach to mitigate potential risk.

**Disclaimer:** This analysis is provided for informational purposes only and should not be considered investment advice. Always consult with a qualified financial professional before making any investment decisions.